Brind.
  1. The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
  2. Viking Therapeutics' drug results were less favorable than Eli Lilly's, leading to speculation that Viking may seek a partnership or acquisition.

GSK and Viking Therapeutics are seeking updates on potential collaboration prospects for drugs targeting NASH and X-ALD.

1 report, 1 independent Updated Jul 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

GSK and Viking Therapeutics are seeking updates on potential collaboration prospects for drugs targeting NASH and X-ALD.

Who's involved

What this event is mainly about
GSKViking Therapeutics

Keep exploring

Part of

Viking Therapeutics' drug results were less favorable than Eli Lilly's, leading to speculation that Viking may seek a partnership or acquisition. All 1 developments

Within The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksViking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports second-quarter 2025 results o